Search
Granisetron
go.drugbank.com/drugs/DB00889ApprovedInvestigationalA serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingProducts: GRANIDUR 3 MG/3 ML ENJEKSIYONLUK ÇÖZELTI, 5 ADET, GRANIDUR 3 MG/3 ML ENJEKSIYONLUK ÇÖZELTI, 1 AMPULIcotinib
go.drugbank.com/drugs/DB11737Investigational. was given a “May Proceed” from the US FDA to conduct a Phase I study for the evaluation of icotinib as a treatment of EGFR+ Non-Small Cell Lung Cancer (NSCLC). … Icotinib is a potent and specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Icotinib was approved in China by the SFDA in June, 2011 and in January 2014, Beta Pharma, Inc
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersInulin
go.drugbank.com/drugs/DB00638ApprovedInvestigationalNutraceuticalA starch found in the tubers and roots of many plants. Since it is hydrolyzable to fructose, it is classified as a fructosan.
Categories: Compounds used in a research, industrial, or household settingKeyhole limpet hemocyanin
go.drugbank.com/drugs/DB05299ApprovedInvestigationalWithdrawnKeyhole limpet hemocyanin is an immune modulator, given as a vaccine to help the body respond to cancer. A natural protein isolated from the marine mollusc keyhole limpet. … Keyhole limpet hemocyanin is an immunogenic carrier protein that, in vivo, increases antigenic immune responses to haptens and other weak antigens such as idiotype proteins.
Etesevimab
go.drugbank.com/drugs/DB15897InvestigationalEtesevimab (LY-CoV016, also known as JS016) is a fully human and recombinant monoclonal antibody that targets the SARS-CoV-2 surface spike protein receptor binding domain. … [L16651,L16661] Under the EUA granted in February 2021, etesevimab is used in combination with [bamlanivimab] to treat mild to moderate COVID-19 in adults and pediatric patients who are at high risk for
Ammonia N-13
go.drugbank.com/drugs/DB09326ApprovedAmmonia N 13 Injection, USP is a positron emitting radiopharmaceutical that is used for diagnostic purposes in conjunction with positron emission tomography (PET) imaging. … Ammonia N 13 Injection, USP is used for imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease
Synonyms: Ammonia N 13, Ammonia N-13Products: Ammonia N 13 N 13, Ammonia N 13NADH
go.drugbank.com/drugs/DB00157ApprovedNutraceuticalNADH is the reduced form of NAD+, and NAD+ is the oxidized form of NADH, a coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage. … It is found widely in nature and is involved in numerous enzymatic reactions in which it serves as an electron carrier by being alternately oxidized (NAD+) and reduced (NADH).
Mixtures: Folika-V, Nutra-ZCategories: Heterocyclic Compounds, 2-RingCaptopril
go.drugbank.com/drugs/DB01197ApprovedInvestigationalCaptopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). … ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Captopril may be used in the treatment of hypertension.
Synonyms: D-2-methyl-3-mercaptopropanoyl-L-proline, D-3-mercapto-2-methylpropanoyl-L-prolineMixtures: CAPTOPRIL E IDROCLOROTIAZIDE HEXAL, CAPTOPRIL E IDROCLOROTIAZIDE SANDOZSodium aurothiomalate
go.drugbank.com/drugs/DB09276ApprovedWithdrawnSodium aurothiomalate is a gold compound that is used for its immunosuppressive anti-rheumatic effects. … Gold Sodium Thiomalate is supplied as a solution for intramuscular injection containing 50 mg of Gold Sodium Thiomalate per mL.
Products: MYOCRISIN INJECTION 20 MG (4% W/V)Fosnetupitant
go.drugbank.com/drugs/DB14019ApprovedInvestigationalFosnetupitant is the pro-drug form of netupitant [FDA label]. … Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg
Categories: Substance P/Neurokinin-1 Receptor Antagonist, Cytochrome P-450 CYP3A Inhibitors